🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524053-14-00
Completed Phase I

Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321

2025-524053-14-00 · tracked via the Priya Life Science EU tracker
Sponsor
Lycia Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
06/03/2026
Enrollment target
48
Sites
Netherlands

Condition studied

Graves Disease

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524053-14-00 on CTIS ↗ ← All trials in the EU